Business Information Security Officer – Commercial IT

Ailux appoints Maria Belvisi, Ph.D., as Chief Scientific Officer. Apr 09, 2026, 20:00 ET * Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision - a program that recently delivered landmark wins in two pivotal COPD trials * Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug development organization, targeting first clinical entry by 2027 * Professor Belvisi will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. SHANGHAI and LONDON, April 9, 2026 /PRNewswire/ - Ailux, an AI-native biotech company discovering and engineering next-generation biologics across multiple indications, today announced the appointment of Maria G. Belvisi, Ph.D. as Chief Scientific Officer. Professor Belvisi brings more than three decades of industry and academic leadership in drug research and development, including nearly a decade at AstraZeneca where she served as Senior Vice President, Research and Development, Respiratory & Immunology, BioPharmaceuticals R&D. She will report to Alex Li, Chief Executive Officer of Ailux. Ailux is an AI-native biotech company headquartered in Shanghai, founded within and wholly-owned by XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab and a global team of approximately 150 across China, the UK, and the US. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is advancing its internal pipeline toward first clinical entry by 2027. Professor Belvisi joined AstraZeneca in 2017 and was accountable for the global Respiratory & Immunology R&D organization spanning approximately 500 scientists across the UK, Sweden, the US, and Spain. During her tenure she built and advanced one of the industry's most innovative and productive early R&I portfolios, with end-to-end responsibility from target identification through Phase 3 investment decisions. Most recently, tozorakimab - a potential first-in-class IL-33 antibody that she championed from early preclinical development through the Phase 3 investment decision - met its primary endpoints in both the OBERON and TITANIA trials in COPD. The results, announced last month, have been widely recognized as landmark for the field and potentially transformational for COPD patients. Alongside her industry career, Maria has held a professorship at the National Heart & Lung Institute, Imperial College London - a position she continues to hold today. During her time leading the Imperial research group, she trained more than thirty PhD students and published over 250 peer-reviewed papers. She also served as Research Director of the European Respiratory Society (2013-2016) and founded IR Pharma, a contract research organization serving major pharmaceutical companies in the respiratory space. In her new role at Ailux, Maria will also establish and lead a UK research site, further expanding the company's presence in one of the world's leading centers for biomedical research and innovation. She is a Fellow of the European Respiratory Society, the British Pharmacological Society, and the Academy of Medical Sciences, and was named one of Endpoints News' "20 Outstanding Women in Biopharma" in 2021. "Maria is exactly the kind of scientific leader Ailux needs at this stage of our journey," said Alex Li, CEO of Ailux. "She has spent her career turning bold scientific hypotheses into medicines that reach patients - building programs from scratch, taking them through the clinic, and doing so at a scale that few have matched. We are building Ailux to go the full distance, and Maria's scientific leadership will be central to every step of that journey." "What drew me to Ailux is the genuine integration of AI and biology - not AI as a tool applied to conventional drug discovery, but as a co-equal foundation for how programs are conceived and built," said Professor Belvisi, CSO of Ailux. "I believe Ailux's platform and team give us a real opportunity to originate first-in-class and best-in-class medicines, and I am excited to join the team and work together to build a global company that can deliver transformative therapies to patients." About Ailux Ailux is an AI-native biotech company headquartered in Shanghai and a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company's global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027. SOURCE Ailux

IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on ide849-imfinzi SCLC trial. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA's investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca's PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach. 8-K event classification. Item 8.01 - Other Events Key terms. clinical collaboration agreement, antibody-drug conjugate, Phase 1 clinical trial, programmed death-ligand 1 (PD-L1) inhibitor, +2 more 04/09/2026 - 06:01 AM Faq. What clinical collaboration did IDEAYA Biosciences (IDYA) announce with AstraZeneca? IDEAYA Biosciences entered a clinical collaboration agreement with AstraZeneca to study IDE849 with AstraZeneca's Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination trial, while AstraZeneca will supply Imfinzi, aiming to evaluate safety and efficacy in this difficult-to-treat cancer. What is IDE849 in the IDEAYA Biosciences (IDYA) and AstraZeneca study? IDE849 is IDEAYA Biosciences' investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate. It targets DLL3, which is reported to be upregulated in several solid tumor types, and is being evaluated for safety and efficacy in a global Phase 1 clinical trial program. Which cancers are targeted in IDEAYA Biosciences' IDE849 Phase 1 trial? The IDE849 Phase 1 trial focuses on DLL3 upregulated solid tumors, including extensive-stage small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma. These cancers have significant unmet medical need, and DLL3's limited expression in normal tissues makes it a promising therapeutic target. Who sponsors and supplies drugs in the IDEAYA (IDYA) and AstraZeneca collaboration? IDEAYA Biosciences will sponsor the clinical combination study evaluating IDE849 with AstraZeneca's Imfinzi. AstraZeneca will supply Imfinzi, a PD-L1 inhibitor, for the trial. This structure lets IDEAYA lead study operations while leveraging AstraZeneca's established immunotherapy agent. Where will IDEAYA Biosciences' IDE849 clinical trial enroll patients? IDEAYA's multi-site global Phase 1 clinical trial for IDE849 plans to enroll patients across North America, Europe, Australia, South America, and Asia. This broad geographic footprint is designed to access diverse patient populations with DLL3 upregulated solid tumors, including small cell lung cancer. Filing exhibits & attachments. 3 documents

Result of AGM. 9 April 2026 Results of Annual General Meeting held on 9 April 2026 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. | / | Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes cast in total | Total votes cast as a % of issued share capital | Votes withheld | | 1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025 | 1,198,663,815 | 99.99% | 166,701 | 0.01% | 1,198,830,516 | 77.29% | 2,309,793 | | 2 | To confirm the 2025 interim dividends | 1,199,596,253 | 99.91% | 1,054,621 | 0.09% | 1,200,650,874 | 77.41% | 489,438 | | 3 | To appoint KPMG LLP as Auditor | 1,200,331,533 | 99.98% | 203,239 | 0.02% | 1,200,534,772 | 77.40% | 605,649 | | 4 | To authorise the Directors to agree the remuneration of the Auditor | 1,200,231,237 | 99.98% | 277,426 | 0.02% | 1,200,508,663 | 77.40% | 631,646 | | 5a | To re-elect Michel Demaré as a Director | 1,181,183,631 | 98.39% | 19,312,258 | 1.61% | 1,200,495,889 | 77.40% | 644,420 | | 5b | To re-elect Pascal Soriot as a Director | 1,188,466,505 | 99.00% | 12,056,196 | 1.00% | 1,200,522,701 | 77.40% | 617,611 | | 5c | To re-elect Aradhana Sarin as a Director | 1,191,427,943 | 99.30% | 8,391,362 | 0.70% | 1,199,819,305 | 77.36% | 1,321,004 | | 5d | To re-elect Philip Broadley as a Director | 1,171,470,116 | 97.59% | 28,983,447 | 2.41% | 1,200,453,563 | 77.40% | 686,746 | | 5e | To re-elect Euan Ashley as a Director | 1,197,441,098 | 99.75% | 3,022,489 | 0.25% | 1,200,463,587 | 77.40% | 676,722 | | 5f | To re-elect Birgit Conix as a Director | 1,200,028,460 | 99.96% | 428,931 | 0.04% | 1,200,457,391 | 77.40% | 683,030 | | 5g | To re-elect Rene Haas as a Director | 1,176,085,879 | 97.97% | 24,361,879 | 2.03% | 1,200,447,758 | 77.40% | 692,663 | | 5h | To re-elect Karen Knudsen as a Director | 1,200,091,469 | 99.97% | 370,843 | 0.03% | 1,200,462,312 | 77.40% | 678,109 | | 5i | To re-elect Diana Layfield as a Director | 1,199,711,377 | 99.94% | 755,622 | 0.06% | 1,200,466,999 | 77.40% | 673,422 | | 5j | To re-elect Anna Manz as a Director | 1,199,171,542 | 99.89% | 1,310,287 | 0.11% | 1,200,481,829 | 77.40% | 658,592 | | 5k | To re-elect Sheri McCoy as a Director | 1,181,129,650 | 98.39% | 19,334,808 | 1.61% | 1,200,464,458 | 77.40% | 675,963 | | 5l | To re-elect Tony Mok as a Director | 1,197,756,109 | 99.77% | 2,702,422 | 0.23% | 1,200,458,531 | 77.40% | 681,890 | | 5m | To re-elect Marcus Wallenberg as a Director | 993,713,162 | 83.80% | 192,121,282 | 16.20% | 1,185,834,444 | 76.46% | 15,305,980 | | 6 | To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025 | 1,161,885,452 | 96.78% | 38,608,771 | 3.22% | 1,200,494,223 | 77.40% | 646,086 | | 7 | To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020 | 1,186,833,063 | 98.89% | 13,376,194 | 1.11% | 1,200,209,257 | 77.38% | 930,948 | | 8 | To authorise limited political donations | 1,176,818,096 | 98.50% | 17,954,803 | 1.50% | 1,194,772,899 | 77.03% | 6,367,525 | | 9 | To authorise the Directors to allot shares | 1,115,450,202 | 92.92% | 84,989,076 | 7.08% | 1,200,439,278 | 77.40% | 701,146 | | 10 | To authorise the Directors to disapply pre-emption rights | 1,113,184,536 | 92.75% | 87,024,695 | 7.25% | 1,200,209,231 | 77.38% | 930,073 | | 11 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 1,053,612,673 | 87.78% | 146,670,037 | 12.22% | 1,200,282,710 | 77.39% | 856,594 | | 12 | To authorise the Company to purchase its own shares | 1,197,748,658 | 99.81% | 2,335,330 | 0.19% | 1,200,083,988 | 77.38% | 1,056,436 | | 13 | To reduce the notice period for general meetings | 1,108,104,727 | 92.31% | 92,307,790 | 7.69% | 1,200,412,517 | 77.40% | 727,904 | Nazneen Rahman retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, she will receive her pro-rata entitlement to non-executive director fees for the month of April 2026. No other remuneration payment or payment for loss of office will be made. A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Issued capital As at 7 April 2026, the number of issued shares of the Company was 1,550,988,781 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca Matthew Bowden Company Secretary AstraZeneca PLC This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.